Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI-1) Trial

Trial Profile

Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI-1) Trial

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs BCT 100 (Primary) ; Cytarabine (Primary) ; Ganetespib (Primary) ; Quizartinib (Primary) ; Sapacitabine (Primary) ; Selinexor (Primary) ; Tosedostat (Primary) ; Vosaroxin (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms AML-LI-1; AML-LI1; AMLM20; LI-1
  • Most Recent Events

    • 06 Dec 2016 Results of preliminary analysis (n=218) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 11 Jan 2016 According to the CTI BioPharma media release, company is planning to discuss potential approval pathways with regulators in the U.S. and EU in 2016.
    • 11 Jan 2016 According to the CTI BioPharma media release, company announced that the United Kingdom's National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group has chosen to advance tosedostat to the second stage of a randomized clinical trial of low-dose cytarabine plus or minus tosedostat in older patients with AML or high risk myelodysplastic syndrome (MDS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top